Protocol Ledger

NCT07871110 · Phase II · RECRUITING

Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventional Phase II clinical trial protocol NCT07871110 sponsored by TransThera Sciences (Nanjing) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-09-18 Enrollment: 182 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07871110
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)182 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07871110
Protocol FieldVerified Registry Value
NCT IdentifierNCT07871110
Consolidated Lead SponsorTransThera Sciences (Nanjing)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment182 participants (ESTIMATED)
Registered Start Date2026-09-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI